Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Interventional Radiology and More for HCC

February 23rd 2018

Locoregional Therapies for Extrahepatic HCC

February 23rd 2018

Managing Locoregional Therapies in HCC

February 23rd 2018

Growing Treatment Landscape in Liver Cancer

February 23rd 2018

Novel Combinations on the Horizon in HCC

February 23rd 2018

Emerging Second-Line Therapies in HCC

February 23rd 2018

Frontline Clinical Trials in Liver Cancer

February 23rd 2018

Sequencing Considerations in HCC

February 23rd 2018

HCC: Nivolumab's Side Effects

February 23rd 2018

Proactive Management of TKI Side Effects in HCC

February 23rd 2018

HCC: Considerations in Toxicity Management

February 23rd 2018

Second-Line Nivolumab in Liver Cancer

February 23rd 2018

Response and Outcomes With TKIs in HCC

February 23rd 2018

HCC: Multidisciplinary Decision-Making

February 23rd 2018

Trends and Risk Factors in Liver Cancer

February 23rd 2018

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

February 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of regorafenib (Stivarga) on the treatment of patients with colorectal cancer (CRC).

Immunotherapy Combination Explored in Unresectable HCC

February 22nd 2018

Investigators are looking into a combination of immunotherapy agents for patients with unresectable hepatocellular carcinoma, for whom there are limited treatment options in the first line.

Dr. Chau on Analysis of Asian and Western Patients With Gastric/GEJ Cancer

February 22nd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.

Gastrointestinal Cancers Entering Age of Precision Medicine

February 21st 2018

Aiwu Ruth He, MD, PhD, discusses the future of precision medicine in gastrointestinal cancers.

Lenvatinib HCC Data Published as FDA Considers Approval

February 20th 2018

Lenvatinib (Lenvima) was noninferior for overall survival while improving progression-free survival compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma.